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Viagra and other erectile-dysfunction (ED) medications are typically associated with older men. 
There is thus little research on their use in college-age men. The purpose of the present study was 
to explore the use of sexual-enhancement drugs (SEDs) in college men and to compare the men 
who had used SEDs to those who had not used them. Eighty-two male college students 
completed a questionnaire that included open-ended questions about their use of SEDs and items 
assessing their sexual history and motives for having sex. The majority of the 16 men who 
reported having used SEDs used Viagra, followed by herbal products and Ecstasy. U er  of these 
substances reported having had more sex partners and endorsed enhancing pleasure as being a 
more important reason for having sex than did those who had not used them. Results suggest that 
















Viagra (sildenafil) is a phosphodiesterase-5 (PDE-5) inhibitor that was originally 
developed for the treatment of angina. It received Food and Drug Administration (FDA) 
approval for the treatment of erectile dysfunction (ED) in the spring of 1998 (Jackson, Gillies, & 
Osterloh, 2005). Due largely to a massive, global, advertising campaign, the drug quickly 
became a cultural icon (Tiefer, 2006), with one million prescriptions written in the US in less 
than two months following its approval and 177 million prescriptions written in over 120 
countries by 2005 (Jackson et al., 2005). With the success of Viagra, the PDE-5 inhibitors 
Levitra (vardenafil) and Cialis (tadalafil) were introduced to the ED-treatment market (Jackson et 
al., 2005).  
The cultural impact of Viagra, particularly its role in the construction of gender and 
sexuality, has been critiqued. Historically, declining sexual functioning was considered a normal 
and acceptable component of the aging process. The advancement of technology in sexual
health, however, has provided new standards for the aging body (Marshall, 2006). This 
technology has both physical and cultural implications, as ED is often conflated with the loss of 
manhood. Viagra can therefore be construed as a tool for the repair and constructi of 
masculinity, contributing to the medicalization of the male body (Loe, 2001). Considering the 
role that Viagra and other ED medications plays in the conceptualization of masculinity and 
sexuality, research concerning these substances can help further the study ofh man sexuality. 
Erectile Dysfunction 
Prevalence estimates of ED are positively associated with age (Feldman, Goldstein, 
Hatzichristou, Krane, & McKinlay, 1994; Laumann, Paik, & Rosen, 1999; Rosen et al., 2004). In 
a national probability sample of men and women ages 18–59, Laumann and colleagues found 
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that 7% of men ages 18–29 and 18% of men ages 50–59 reported trouble obtaining or 
maintaining an erection. In a multinational study by Rosen et al. (2004), 16% of men ages 20–75 
reported experiencing erectile difficulties. Self-reported ED increased relatively linearly with 
increasing age. For example, 8% of men between the ages of 20 and 29, 15% between 40 and 49, 
and 37% between 70 and 75 reported the condition (Rosen et al., 2004).  
Erectile dysfunction has been associated with various psychological characteristics.  
Compared with healthy men, men seeking treatment for ED have endorsed experiencing lower 
satisfaction with their sexual lives as well as with their overall lives (Mallis et al., 2006). Latini, 
Penson, Wallace, Lubeck, and Lue (2006) found that compared with men with less severe ED, 
men with more severe ED reported poorer functioning across various psychological domains, 
including belonging/loneliness, positive affect, depression, sexual self-efficacy, and well-being. 
Men with mild ED were more likely to be classified as having nonorganic ED than those with 
severe ED, and the latter group reported worse psychological outcomes than the former gr up 
(Latini et al., 2006). Improvements in self-esteem, confidence, sexual relationship satisfaction, 
and overall relationship satisfaction were found in men with ED after treatment with Viagra, 
compared with a placebo (Althof et al., 2006). Erectile dysfunction, particularly more severe 
expressions of it, thus appears to be related to a variety of adverse psychosocial outcomes. It is 
important to note, however, that these studies do not indicate that erectile problems cause uch 
outcomes.     
Despite the psychosocial factors associated with ED, up to 70% of men with the 
condition do not seek treatment for it (Kubin, Wagner, & Fugl-Meyer, 2003). Research suggests 
that less than 16% of men with ED maintain their use of PDE-5 inhibitors (Rosen et al, 2004). A 
multinational study of men with ED found that few men with mild ED reported perceiving their 
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condition as permanent, but the majority of those with severe ED perceived it as such (Fi her et 
al., 2004). The authors also found that 10%, 23%, and 33% of the men with mild, moderate, and 
severe ED, respectively, had used Viagra on multiple occasions. The number of men who had 
used Viagra more than once increased by decade from the participants in their 20s to those in 
their 50s and dropped slightly when men reached their 60s and 70s. Overall, Fisher and 
colleagues found that men were more likely to use Viagra if they perceived their erect le 
difficulties as severe, believed that ED medication is safe, and perceived support from referent 
others.  
Viagra Use in Non-ED Samples   
Few studies have explicitly examined the use of Viagra and other ED drugs in college-
age samples. Some research, however, has explored the effects of Viagra in individuals without 
ED as well as the recreational use of the medication. Kamin, Zion, Chudakov, and Belmaker 
(2006) examined the effects of Viagra on a sample of men without ED, ages 22–34. The men 
ingested Viagra for 2 weeks and placebo for 2 weeks at home, respectively, one hour b fore 
having sex and rated their experiences. The researchers found no major effects of the drug on 
sexual functioning when compared with placebo. Another study with asymptomatic men, ages 
28–37, found a reduction in post-ejaculatory refractory times for Viagra when compared with a 
placebo but found no differences in seminal or erectile parameters (Aversa et al., 2000). 
The majority of studies regarding recreational use of Viagra fall within the HIV-
prevention literature, and most of them focus on men who have sex with men (MSM; Smith & 
Romanelli, 2005; Swearingen & Klausner, 2005). A study that annually surveyed British 
nightclub attendees for Viagra use from 1999 to 2003 found from its 2003 data that 17% of the 
men had used Viagra at some point in their lives and that 6% had used it in the past month 
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(McCambridge, Mitcheson, Hunt, & Winstock, 2006). The authors concluded that the men might 
have been using it to overcome the temporary erectile difficulties associated wth alcohol and 
stimulant drugs. Halkitis, Moeller, and DeRaleau (2008) found a significant relationship between 
steroid use and recreational use of ED medications in MSM who attend gyms in New York City. 
Swearingen and Klausner (2005) reviewed 14 studies concerning Viagra use, sexual ri k 
behavior, and sexually transmitted infections (STIs). The majority of the studies rev wed 
involved MSM, who had a range of Viagra use from 3% to 32%; furthermore, several of the 
studies found an association between ED medication use and sexual risk behavior (e.g., 
unprotected anal sex) and increased risk for STIs. Most of the reviewed studies employed 
convenience samples, and their rates of Viagra use might thus not reflect that in the general 
population. When recreational use of Viagra and other ED medications occurs concurrently with 
club drugs (e.g., ecstasy), users may be at risk for fatal drug interactions (Smith & Romanelli, 
2005).     
Viagra Use in College-age Men 
Two studies were found that specifically focused on the use of Viagra and other ED 
medications in college-age men. Musacchio, Hartrich, and Garofalo (2006) examined ED an  
ED medication use in a sample of 234 sexually active men, ages 18–25, from three Chicago 
universities. Thirteen percent of the sample reported ED, defined as ever having difficulty 
obtaining or maintaining an erection, and 25% of the sample reported ED with condom use. 
Viagra and other ED medications were used by 6% of the sample (14 men). Of these men, 54% 
reported obtaining the medications from friends, and 39% reported obtaining them from other 
non-medical sources (source was missing for one participant). Reported reasons for using the 
drugs included treating ED (57%), having more sex (29%), and other reasons (14%). 
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Furthermore, 64% of the men who used ED medications did so with other substances such as 
alcohol, marijuana, and GHB (Musacchio et al., 2006).  
A recent study explored the use of PDE-5 inhibitors in a sample of 360 men drawn from 
18 randomly selected colleges in Brazil, ages 18–30 (Freitas, Menezes, Antonialli, & 
Nascimento, 2008). None of the students reported receiving a medical diagnosis of ED. Fifteen 
percent of the participants (53 men) reported previously using PDE-5 inhibitors, with 53% using 
Viagra, 37% using Cialis, and 10% using Levitra. Reasons for using these medications included 
curiosity (70%), improving erection (12%), avoiding premature ejaculation (12%), and 
increasing pleasure (6%; Freitas et al., 2008).   
The Present Study 
   There is thus a dearth of research examining the use of Viagra and other ED medications 
in college-age men. Research suggests that these men—even those with normal erectile 
functioning—do sometimes use these drugs. The present study used qualitative and quantitative 
methods to explore the use of sexual-enhancement drugs and other substances in college-age 
men. More specifically, it has two major objectives. The first objective concerns ollecting 
descriptive data, such as which sexual-enhancement drugs or other substances were used, the 
reasons for using them, and sexual behaviors and motivations of the men who used them. The 
second objective is to compare the men who have used sexual-enhancement drugs or substance  
with those who have not used them on a variety of variables, including sexual experience and 
motivation. We broadly use the term sexual-enhancement drugs (SEDs) to include the PDE-5 
inhibitors, such as Viagra, in addition to other non-pharmaceutical products, such as herbal 






Participants were male introductory psychology students at the University of Kansas. 
They participated as one way to fulfill a course research requirement. At the beginning of each 
semester, students in this course complete an online screening survey. This survey includ s
general demographic questions, as well as specific questions related to studies being conducted 
that semester. For this study, the following question was used in the screening survey: 
Have you ever tried any drug or other substance aimed at enhancing sexual performance? 
For example, this could include drugs such as Viagra, Cialis, or Levitra, or herbs or other 
substances, such as maca root, yohimbe extract, or goat weed, or anything aimed at 
enhancing sexual performance. This could include a prescription drug, an over-the-
counter drug or herb, or any other drug or herb. 
Out of the 1,248 male students who completed the survey, 58 (4.65%) answered “Yes” to 
this question. All the men who answered “Yes” were informed that they were eligible to sign up 
for this study. A small percentage (randomly determined) of the men who answered “No” were 
also informed that they were eligible; our reasons for including these men were to provide a 
comparison group of SED nonusers and to increase participants’ privacy by including some 
participants who had used these drugs/substances and some who had not. They did not know the 
topic of the study in advance. Data were collected across two semesters.   
An initial sample of 89 male students participated in the study. Seven were disqualified: 
Three did not follow the instructions; three failed a carefulness check, described below; and one 
was an international student, who was excluded because of the impact that culture has on sexual 
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behaviors and attitudes. The final sample consisted of 82 men, 16 of whom endorsed using SEDs 
(users).   
The mean age of participants was 19.65 years (SD = 2.37; range = 18–31). Users (M = 
20.75, SD = 3.68) were significantly older than nonusers (M = 19.38, SD = 1.87), F(1, 80) = 
4.50, p = .037. Table 1 presents data on race/ethnicity, sexual orientation, and relationship status. 
The majority of the participants identified as European American/White and heteros xual. Most 
participants reported not dating anyone at the time of the study (44.44%) or dating one person 




















 Nonusers       Users 
Characteristic n %  n % 
Race or ethnicitya 
    African American or Black 
    European American or White 
    Hispanic American or Latino 
    Biracial or Multiracial 
    Other 
Sexual Orientation 
    Heterosexual 
    Homosexual 
    Bisexual 
Relationship Statusb 
    Never dated anyone 
    Not dating anyone now 
    Dating one person casually 
    Dating more than one person casually        
    Dating one person exclusively 
    Engaged 
    Married 













































































Note.  Unless otherwise noted, n = 66 nonusers and n = 16 users. 
aNo one checked Asian American or Native American or American Indian. 





 The questionnaire consisted of three sections (see Appendix A). Section 1 asked about 
previous use of “substances aimed at enhancing sexual performance” and provided examples 
(i.e., “Drugs such as Viagra, Cialis, or Levitra,” “Commercially avail ble performance enhancers 
such as Enzyte,” “Herbs or other substances, such as maca root, yohimbe extract, goat weed, 
topical creams, etc.”). Participants were then asked to check which of the following three options 
applied to them: (a) “I have used a drug or other substance aimed at enhancing sexual 
performance,” (b) “I have not used a drug or other substance aimed at enhancing sexual 
performance, but I know guys who have,” (c) “I have not used a drug or other substance aimed at 
enhancing sexual performance, and I do not know any guys who have.” For the second semester 
of data collection, the final two options were changed to “I have not used a drug or other 
substance aimed at enhancing sexual performance, but I have done something similar to this” 
and “I have not used a drug or other substance aimed at enhancing sexual performance, and I 
have not done something similar to this,” respectively. We altered these responses to identify 
participants who had used SEDs but did not view themselves as doing so (false-negatives). 
 Participants who endorsed (a) having used SEDs were instructed to answer the questions 
in Section 1 based on their experience, choosing the time that stood out most if they had multiple 
experiences. Men who endorsed (b) not having used SEDs but knowing men who had were 
instructed to answer questions the way they thought such men would answer them. Participants 
who endorsed (c) not having used SEDs and not knowing men who had (first semester) or not 
having done something similar (second semester) w e instructed to answer questions the way 
they thought a man might answer them if he had used such drugs or substances. The second 
semester participants who checked (b) not having used SEDs but having done something similar 
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were instructed to answer the questions based on their experience, choosing the time t at stood 
out most if they had multiple experiences. We asked all participants to write answ rs regardless 
of their previous behaviors to protect their privacy.  
Participants then completed a general item asking them to describe the situation (i.e., 
what led up to the situation, what substance they used, and what happened in the situation). The 
remainder of Section 1 included more specific open-ended questions, including how they 
obtained the drug or substance, their reasons for taking it, expected and actual consequences, and 
other drugs or substances used at the time. This section also included two closed-ended qustions 
that asked respondents to indicate the sexual activities in which they engaged when using the 
SEDs and to indicate their relationship status at the time they used them.   
 Section 2 consisted of general items that all participants answered based on their wn 
experiences. The first item provided a list of SEDs and asked the participants to indicate the 
number of times they had used each item that they endorsed. The remaining questions focused on 
topics such as general drug-use history, erectile difficulties, opinions and attitu es regarding sex, 
and desired and actual sexual outcomes. Section 2 also included the Sex Motives Scale (SMS; 
Cooper, Shapiro, & Powers, 1998).   
The SMS (Cooper et al., 1998) is a 29-item, self-administered measure that is based on a 
functionalist perspective of human behavior and consists of two dimensions (i.e., approach vs. 
avoidance, autonomy vs. relatedness). These two dimensions cross to form four broad categories 
of motives: self-focused approach, self-focused aversive, social approach, and social aversive 
motives (Cooper et al., 1998).  
 Participants indicated how important each of the reasons was to them, using a scale 
ranging from 1 (not at all important) to 5 (extremely important). Cooper at al. (1998) reported 
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that the items load onto six factors: intimacy motives (e.g., “How important is it for you to have 
sex to become closer with your partner?”), enhancement motives (e.g., “How imp rtant is it for 
you to have sex just for the excitement of it?”), self-affirmation motives (e.g., “How important is 
it for you to have sex because it makes you feel more self-confident?”), coping motives (e.g., 
“How important is it for you to have sex because it helps you feel better when you’re feeling 
low?”), peer pressure motives (e.g., “How important is it for you to have sex so that others won’t 
put you down about not having sex?”), and partner approval motives (e.g., “How important is it 
for you to have sex because you worry that your partner won’t want to be with you if you 
don’t?”). Each scale has five items, except for partner approval, which has four items. Intimacy 
and enhancement are social approach and self-focused approach motives, respectively. Self-
affirmation and coping are self-focused aversive motives, and peer pressure and partner approval 
are social aversive motives. 
 Studies in both college student and community samples have demonstrated the 
psychometric adequacy of these scales. Data from a community sample of sexually experienced 
college students, with an average age of 21.5 years, yielded the following reliability coefficients 
(Cronbach’s alpha), respectively: .90, .87, .89, .69, .87, and .84. The sex motives also related to 
distinctive patterns of sexual risk taking (Cooper et al., 1998). We included a carefulness check 
within the SMS that instructed participants to “cross out the one” to show that they are reading 
the items.       
 Section 3 included questions about demographic information and sexual behaviors. It 
presented a list of sexual activities and asked participants to indicate whether or not they had 
engaged in each, the number of times they had done so, and the number of individuals with 
whom they had engaged in each behavior. A question also asked respondents to indicate the 
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number of individuals with whom they had engaged in sexual activity (including oral, penile-
vaginal, and/or anal sex) during the past year. We assessed lifetime sexual history by asking 
participants to indicate the age at which they had engaged in various sexual activities for the first 
time and the number of people with whom they had engaged in these activities. Finally, a 
question asked about masturbation frequency; it provided a list of response options ranging f om 
having never masturbated to doing so multiple times a day.          
Procedure 
 Participants anonymously completed the questionnaire in groups of no larger than 15. 
They were seated in alternate seats to protect their privacy. They were giv n a consent form to 
read, which included the purpose of the study and their rights as participants. The questionnaire 
was structured so that everyone could complete it, regardless of their experiences with SEDs. 
When finished, participants turned in their completed questionnaires in manila envelopes and 
were given a debriefing form. The study was approved by the university’s institutional review 
board. See Appendices B, C, and D for the consent form, debriefing form, and protocol, 
respectively.   
Data Analysis 
 We first analyzed the participants’ experiences of using SEDs reported in Section 1 of the 
questionnaire. For these analyses, we only used the data from participants who had used an SED. 
We used the constant comparison method (Glaser & Strauss, 1967) to code the responses. More 
specifically, we and a group of undergraduate research assistants developed and mo ifie coding 
categories based on themes that emerged from the narratives. Participants’ responses were coded 
with these categories. We supplemented frequencies of the user characteristics with quotes from 
their narratives to illustrate the findings. 
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 Before analyzing participants’ reports of their sexual activity during that the past year 
(number of times and individuals) and lifetime (age at first time, number of individuals), we 
checked the data for inconsistencies. For example, the number of individuals with whom a 
participant engaged in a sexual activity in the past year should have been less than or equal to the 
number of individuals with whom he has ever engaged in the sexual activity. In the few cas s 
inconsistencies could not be resolved, we treated the data as missing.  
Although we requested numerical responses for the sexual activity questions, many 
participants wrote answers such as “a lot” or “not sure.” We estimated these data for past year 
number of times and past year and lifetime number of individuals, respectively, by using the 90th 
percentile scores for each sexual activity. We assumed that if a participan  did not know or 
remember how many times or with how many people he had engaged in an activity, he likely did 
so many times or with a lot of people, respectively. For the number of times activities were 
performed during the past year, we analyzed only penile-vaginal intercourse (PVI) and 
performing penile-anal intercourse (PAI). Respondents’ estimates of thenumber of times they 
engaged in these activities were likely more accurate than those for activities such as kissing, and 
only one participant reported ever receiving PAI. If the 90th percentile score for the number of 
individuals with whom a participant engaged in a sexual activity was greater th n the number of 
individuals with whom he had ever engaged in the activity, we used the lifetime respons  as the 
estimate for the past year response. We did not estimate participants’ age for engaging in each 
behavior for the first time, and we treated inappropriate responses (e.g., nonnumeric responses 
that did not suggest a particular age) as missing. 
 Next, we compared user and nonuser data with each other. We used chi-square analyses 
to compare their frequencies of engaging in each sexual activity. Chi-square might not have been 
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valid in these tests because 25% or more of the cells had expected values less than five, so we 
derived p from Fisher’s exact test. We then analyzed the continuous sexual activity data (e.g., 
number of sexual partners for various behaviors) using multiple analyses of variance 
(ANOVAs). Our rationale for performing multiple ANOVAs and thus increasing the risk for 
Type I Error was that the study is exploratory and we did not want to lose participants who did 
not report engaging in certain activities.  
Finally, we compared the user and nonuser SMS data using a MANOVA and analyzed 
the individual factors via the univariate tests.    
Results 
SED User Characteristics 
 SEDs used. Table 2 lists the SEDs reported by the users. Seven participants (43.75%) 
described a situation in which they used Viagra. Three participants (18.75%) reported using 
multiple SEDs but did not indicate which specific experiences they were discussing in their 
narratives. Their narratives likely consisted of an amalgamation of multiple episodes of SED use. 
For example, one man wrote, “last Summer I worked at [name of supplement company] so was 
able to try a lot of products for relatively no charge” (Participant #203; except for correcting 
misspellings, quotes are verbatim), and he later reported having used Enzyte, yohimbe extract, l-
arginine, and Ecstasy for the purpose of enhancing sexual performance via the list of SEDs 
provided in Section 2 of the questionnaire. The other two participants who reported using 
multiple SEDs used Viagra and Cialis and Viagra and Pro Solutions, respectively. The majority 
of the users (56.25%) thus reported having used Viagra.  
 Many participants reported using substances other than PDE-5 inhibitors. Although it is 
considered a recreational drug, two men described situations in which they used Ecstasy to 
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enhance their sexual performance. One man reported using a topical cream calld Mandelay. 
Participant #126 wrote, “I do not remember exactly what the name of the substance was alled 
but I believe it had the word blue in it and it was a shot of some type of liquid.” Based on this
response, we classified him as using Liquid Blue, which is sold as a male sexual-enhancement 
product. 
The source of the SEDs. Although seven men described situations in which they used the 
prescription drug Viagra, only one man reported having a prescription for it at the time (see 
Table 2). Three participants who had used Viagra described obtaining it from a friend o  
coworker. Two participants who had used Viagra described stealing or taking it fromsomeone—
that is, they obtained the drug from someone without that person’s knowledge or consent. For 
example, Participant #130 wrote, “I found one in my father’s medicine box, and tried one,” and 
Participant #136 wrote, “In my buddy’s house there was a prescription of Viagra. I stole one took 
it. It worked and I proceeded to sexual intercourse.” The remaining man who used Viagra wrote, 
“When I was in Mexico over spring break of that year [senior year of high school] I f und some 
Viagra for sale there in a shop at my resort” (Participant #240). We coded his source as Other, as 
opposed to Retail or store, because purchasing the SED from a resort in Mexico is qualitatively 
quite different from purchasing it at a retail store. We coded a participant who reported obtaining 
SEDs by working at a supplement store (Participant #203) as Otherbecause having access to 
products due to one’s employment is a different experience than purchasing them ata store.  
Three men (18.75%) reported obtaining the SEDs from the internet; two of these three 
men described using multiple SEDs. One of the men who reported using Ecstasy reported 
obtaining it from “drug dealers. Non-pharmaceutical means” (Participant #112).   





Characteristic n % 
SED 
    Viagra 
    Enzyte 
    Magna RX 
    Ecstasy 
    Liquid Blue 
    Topical Cream 
    Multiple SEDs 
Source 
    Prescription 
    Friend or coworker 
    Relative 
    Sex partner 
    Retail or store 
    Internet 
    Drug dealer 
    Stolen or taken 









































When they used the SEDs. The mean age at which participants used the SEDs was 19.17 
years (SD = 2.69; range = 16–27). One user did not clearly indicate an age. Five of the men who 
reported using SEDs (31.25%) did so when they were 17 years old or younger. One man 
described an experience that occurred when he was 27; the remaining users were 21 or younger 
at the time.   
Reasons for using SEDs. As shown in Table 3, half of the users reported reasons for using 
SEDs that concerned curiosity or experimentation. For example, the participant who reported 
buying Viagra at a resort in Mexico wrote, “I was curious because I had done a big project over 
erectile dysfunction and I wanted to test the products I researched” (Participant #240). Four of 
the men (25%) reported using the SED to enhance their sexual performance or experience ( .g., 
“use it for lasting longer,” Participant #127). Notably, three men (18.75%) reported using SEDs 
because of sexual difficulties; Participant #231 indicated that he “was having problems with 
premature ejaculation or erectile dysfunction” and Participant #136 reported that he “got whiskey 
dick and couldn’t get a boner.” One man (Participant #203) reported using multiple SEDs 
because they were “free and I wondered if they worked,” which we coded as Curio ity and Other 











Reasons for using SEDs 
  
Reasons n % 
Erectile or sex difficulties 
Curiosity or experimentation 
Increase penis or erection size 















Note. SED = sexual-enhancement drug.  
Percentages do not add to 100% because some  
participants reported multiple reasons for using  
the SED. 
 
   
  Expected and actual consequences for using SEDs. Overall, the men who used SEDs 
reported expecting positive consequences concerning enhancing sexual functioning (see Table 
4). For example, one man wrote, “I expected buck wild crazy sex all night, but once you run t 
of energy, you just run out of energy” (Participant #209). Another respondent wrote “pleasing 
women” (Participant #121) as an expected outcome of using the SED. The modal negative 
consequence expected by the users was financial concerns—but this was reported by nly two 
men (12.50%). Interestingly, three users (18.75%) reported expecting no consequences.   
The SED users also reported actually experiencing largely positive consequences. Four 
participants (25.00%) indicated that using the SED resulted in their “lasting longer” during 
sexual activities, and three (18.75%) described obtaining multiple erections. Participant #127 
wrote the following narrative:  
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What led up was my girlfriend having a house to herself and inviting me over for a night. 
I used Viagra in order to be able to go multiple times, what happened in the situation was 
what was intended I was able to go multiple times. (Participant #127) 
None of the participants discussed pleasing their sex partner as a consequence of using 
the SED. Mirroring the expected consequences, two men (12.50%) described the drug’s cost as a 
negative outcome of using it. Both of these men reported using multiple substances, including 
Viagra. Two men (12.50%)—who had used Viagra and Liquid Blue—reported experiencing no 
consequences from using the SED. One man reported expecting “Nothing, as I knew I didn’t 
have any sexual arousal problems”; he reported that, as expected, “Nothing happened” 
(Participant #106). Another man reported expecting “better more enjoyable sex” but finding that 
















Consequences from Using SEDs 
   
 Expected       Actual 
Consequence n %  n % 
Positive 
    Enhance erection    
    Obtain an erection    
    Obtain multiple erections    
    Enhance sex experience    
    Last longer      
    Increase sex drive   
    Please sex partner 
Negative 
    Money or cost 
    Medical risks    
    Legal risks 
    Inconvenience of SED  
    Erection not go down   







































































Note. SED = sexual-enhancement drug. Percentages do not add to 100%  
because some participants reported multiple expected and/or actual  




Relationships and sexual activities performed when using SEDs. Table 5 lists the 
frequencies of the sexual behaviors performed while using the SEDs and the users’ relationships 
with the individuals with whom they engaged in these behaviors. All of the users reported 
engaging in sexual activity when they used the SED; 15 reported engaging in sexual activity with 
another person, and one reported only masturbating. Fourteen of the 16 users (87.50%) reported 
engaging in PVI. Both of the participants who performed PAI also engaged in PVI.  
The modal response for the users’ relationship with their sexual partners was girlfriend 
(37.50%) followed by a one-night stand or someone they had just met (18.75%; e.g., 
“friend/stranger met her earlier that night,” Participant #203). Concerning their relationship at the 
time they used the SEDs (see Table 6), seven men (43.75%) reported dating one person 
exclusively; these participants consist of the six men who engaged in sexual activity with their 
girlfriend and the man who engaged in sexual activity with a dating partner, respectively.  
Table 5 
Characteristics of Sexual Activities during SED Use     
Characteristic n % 
Relationship with sexual partner 
    No sexual activity with another person  
    Girlfriend                           
    Dating partner 
    Friend  or acquaintance 
    Friend with benefits 
    One-night stand or someone just met 



















Table 5 (continued) 
Characteristics of Sexual Activities during SED Use     
Characteristic n % 
 Sexual activitya 
    Kissing 
    Having someone stimulate your genitals 
    Stimulating someone’s genitals 
    Performing oral sex 
    Receiving oral sex 
    PVI 
    Performing PAI 
    Receiving PAI 





















Note. SED = sexual-enhancement drug; PVI = penile- 
vaginal intercourse; PAI = penile-anal intercourse.  
aPercentages do not add to 100% because most participants  











Relationship Status at Time of SED Use     
Relationship  n % 
Never dated anyone 
Not dating anyone at the time 
Dating one person casually 
Dating more than one person casually 











Note. SED = sexual-enhancement drug. 
 
Other substances used during SED use. Eight of the participants reported using alcohol 
and/or recreational drugs at the time they used the SED, as is shown in Table 7. Reported 
recreational drugs included marijuana, cocaine, and Ecstasy (this participant did not report using 
Ecstasy for sexual-enhancement purposes). Three men (18.75%) were unclear about their use of 
alcohol and recreational drugs; for example, one respondent wrote that he used “everything 
except heroine and crystal meth” (Participant #112). A few men reported that using alcohol 
and/or recreational drugs influenced their decision to use the SED; Participant #136, for 
example, wrote that he used the SED “Because I got whiskey dick and couldn’t get a boner.” 
 Some of the participants also reported that they had been using psychiatric medications at 
the time they used the SED (e.g., Adderall, Lamictal, Seroquel, Xanax). One man noted that his 
using Adderall influenced his decision to use Viagra because “Adderall also kills your tiffy” 
(Participant #136). Seven (43.75%) of the users indicated using substances to enhance physical 
29 
 
performance, such as products containing protein and creatine, and none of them described the 
substances as influencing their decision to use an SED. 
Table 7 
Other Substances Used at Time of SED Use 
Substance n % 
Alcohol and recreational drugs 
    None 
    Alcohol 
    Alcohol and recreational drugs 
    Vague  
Mental-performance enhancing substances 
    None 
    Adderall  
    Caffeine 
Physical-performance enhancing substances     
    None 
    Athletic supplements 
Prescription drugs 
    None 







































Comparisons between SED Users and Nonusers 
Sex Motives Scale. A MANOVA indicated a difference between the SED users and 
nonusers in the SMS data, Wilks’ Lambda = 0.85, F(6, 75) = 2.28, p = .04. The univariate 
analyses revealed that the users endorsed the enhancement motives as being more important 
reasons for them to have sex than did the nonusers, F(1, 80) = 8.26, p = .0052 (see Table 8). We 
found no other significant differences between the two groups among the SMS factors.    
Table 8 
Sex Motives Scale (SMS) Subscale Scores of the SED Users and Nonusers  
 
 Nonusers  Users   
SMS subscales M SD  M SD  F 
Intimacy Motives      3.98     0.97      4.24     0.97      0.88 
Enhancement Motives      4.03     0.82      4.64     0.36      8.26** 
Self-Affirmation Motives      2.78     0.88      2.73     1.13      0.05 
Coping Motives      2.38     0.83      2.65     1.08      1.23 
Peer Pressure Motives      1.45     0.65      1.45     0.62      0.00 
Partner Approval Motives     1.64     0.77      1.69     0.80      0.05 
Note. SMS subscale scores can range from 1 (not at all important) to 5 (extremely important). 
SED = sexual enhancement drug.  
** p < .01.  
 
 
 Sexual activities. Tables 9 and 10 summarize the sexual activity data for SED users and 
nonusers. Penetrative PAI yielded the most differences between the two groups. We did not 
include receptive PAI in the analyses because only one man reported having ever engag d in this 
activity. More of the users than the nonusers reported performing PAI in the past year (53.33% 
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and 20%, respectively) and across their lifetime (56.25% and 21.88%, respectively). 
Furthermore, participants who had used SEDs reported performing PAI with more individuals 
over the past year (M = 0.73 and M = 0.20, respectively) and lifetime (M = 1.19 and M = 0.28, 
respectively) than their nonuser counterparts. We did not find such differences, however, in the 
number of times participants engaged in penetrative PAI or the age at which they first ngaged in 
the behavior.  
 Differences between SED users and nonusers in PVI also emerged from the data butno  
to the same extent as PAI. Although users were not more likely to have engaged in PVI uring 
the past year or their lifetime, they had engaged in PVI with more sex partners (M = 8.75) during 
their lives than did nonusers (M = 4.87). In contrast to the PAI findings, SED users also engaged 
in PVI more times (M = 76.07 times) during the past year than did nonusers (M = 41.95 times). 
Interestingly, we found no differences in the age at which the participants engaged in the various 
sexual activities for the first time. The users were older than the nonusers, however, and still 
might have had more time to find partners even if they did not start doing so earlier in life.
 Participants indicated how often they currently masturbate on a scale ranging from I have 
never masturbated to I masturbate more than once a day. We dichotomized the scale into once a 
week or less and more than once per week. Twelve users (80.00%) and 41 nonusers (64.06%) 
reported masturbating more than once per week, respectively (not a significant difference, 








Numbers and Percentages of the SED Users and Nonusers Who Reported Having Engaged in 
Various Sexual Activities 
 Nonusers  Users   
Sexual Activity n %  n %  p 
Past year 
Kissing 65 98.48  15 93.75  .35 














Stimulating someone’sa     













Performing oral sex 49 75.38  14 87.50  .50 
Receiving oral sex 55 83.33  14 87.50  1.00 
PVI 51 77.27  14 87.50  .50 
Performing PAIb 13 20.00  8 53.33  .02* 
Receiving PAI 1 1.56  0 0  1.00 
Lifetime prevalence 
Kissingc 65 100  16 100  .45 














Stimulating someone’s   
















Table 9 (continued) 
Numbers and Percentages of the SED Users and Nonusers Who Reported Having Engaged in 
Various Sexual Activities 
 Nonusers  Users   
Sexual Activity n %  n %  p 
Lifetime prevalence 
Performing oral sexf 53 81.54  15 93.75  .45 
Receiving oral sexg 57 87.69  15 93.75  .68 
PVIh 52 80.00  15 93.75  .28 
Performing PAIi  14 21.88  9 56.25  .01* 
Receiving PAIj 1 1.59  0 0  1.00 
Note. SED = sexual enhancement drug; PVI = penile-vaginal intercourse; PAI = penile- 
anal intercourse. Unless otherwise noted, n = 66 nonusers and n = 16 users. For these  
analyses, p was based on Fisher’s exact test; chi-square tests might not have been valid  
because some of the cells had an expected value less than 5. 
an = 65 nonusers and 16 users. 
bn = 65 nonusers and 15 users. 
cn = 65 nonusers and 16 users.  
dn = 65 nonusers and 16 users. 
en = 65 nonusers and 16 users. 
fn = 65 nonusers and 16 users. 
gn = 65 nonusers and 16 users. 
hn = 65 nonusers and 16 users. 
in = 64 nonusers and 16 users. 
jn = 63 nonusers and 15 users. 








Sexual History Variables for the SED Users and Nonusers  
 Nonusers  Users   
Sexual activity M SD  M SD  F 
Number of sexual partners for this behavior during the past year 
Kissing 5.83 6.06  6.56 6.43  0.18 




























Performing oral sex 1.58 2.12  2.75 4.04  2.59 
Receiving oral sex 2.57 2.72  3.19 4.15  0.52 
PVI 2.40 2.74  3.13 3.95  0.75 
Performing PAI 0.20 0.40  0.73 0.88  12.68*** 
Number of sexual partners for this behavior across their lifetime 
Kissing 22.75 24.02  32.70 19.19  2.21 




























Performing oral sex 3.26 3.79  7.00 8.70  6.60* 
Receiving oral sex 7.10 11.19  11.91 14.77  2.04 
PVI 4.87 6.08  8.75 8.40  4.40* 
Performing PAI 0.28 0.58  1.19 1.42  15.96*** 
Age of first experience with this sexual behavior 




Table 10 (continued) 
Sexual History Variables for the SED Users and Nonusers  
 Nonusers  Users   
Sexual activity M SD  M SD  F 
Age of first experience with this sexual behavior 




























Performing oral sex 16.32 1.37  16.40 1.68  0.04 
Receiving oral sex 16.26 1.20  15.67 1.68  2.46 
PVI 16.63 1.12  16.07 1.27  2.63 
Performing PAI 17.79 1.53  16.56 6.00  0.55 
Estimated number of times they engaged in selected sexual behaviors in the past year 
PVI 41.95 50.57  76.07 48.44  5.32* 
Performing PAI 1.09 6.21  1.71 2.79  0.13 
Reported number of sex partners in the past year (including oral sex, PVI, and/or PAI) 
Number of partners 3.51 4.05  4.13 4.38  0.29 
Note. SED = sexual enhancement drug; PVI = penile-vaginal intercourse; PAI = penile- 
anal intercourse. We excluded receiving PAI from these analyses because only one  
participant reported having ever engaged in this activity.   




 Sixteen participants reported using a substance to enhance sexual performance. Of the 
men who completed the screening questionnaire, 4.65% endorsed using a substance to enhance 
sexual performance. This percentage is somewhat lower than that found by Musacchio and 
colleagues (2006; 6%) and much lower than that found by Freitas and colleagues (2008; 15%). 
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Considering that the current study had more inclusive criteria for SEDs than did these two 
studies, it is interesting that the screening question resulted in a smaller prevalence than they 
found. These findings, however, must be interpreted with caution because the majority of these 
men did not participate in the study, and the behaviors they were referencing are thus unclear.    
Characteristics of SED Users 
 Viagra was the most commonly used SED, followed by herbal blends (e.g., Enzyte, 
Magna RX, Liquid Blue) and Ecstasy. Although the efficacy of herbal and plant-derived 
products is unclear, they are popular alternatives to medical approaches for sxual health; 
furthermore, these products are not regulated by the FDA, and can be easier to obtain and 
cheaper to purchase than the PDE-5 inhibitors (Rowland and Tai, 2003). The SEDs reported in 
this study promote a variety of claims, such as ED treatment (Viagra), penis enhancement 
(Magna RX), and premature ejaculation prevention (Mandelay). 
 Although it is often viewed as a club drug, two men reported using Ecstasy for sexual 
purposes. These participants’ conceptualizations of the drug as a means of enhancing sexual 
performance suggests that their experiences might have been qualitatively different f they had 
used them for other recreational purposes (e.g., to enhance a rave experience). Ecstasy can 
enhance sexual experiences by increasing physical sensation and sexual desire. It can also, 
however, result in temporary ED, and there are reports of men using Viagra along with Ecstasy 
(“sextasy”) to overcome these effects (Smith & Romanelli, 2005). Neither of the men who used 
Ecstasy to enhance their sexual experiences reported erectile difficulties or the use of an ED 
medication to treat such effects. Furthermore, a participant who had access to multiple herbal 
products due to his job reported using alcohol, cocaine, and Ecstasy, noting that he used the 
SEDs but did not need them.    
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 Only one of the men who used Viagra reported obtaining it from a medical professional, 
and the means by which the other men obtained the drug included receiving it from a friend or 
coworker and taking it from someone. These findings are consistent with those of the before-
mentioned studies of ED medication use in college-age men in that the majority of these men did 
not have prescriptions for the medication.   
 Most of the men who reported using SEDs did not indicate that they were experiencing 
sexual difficulties when they took them. They discussed reasons relating to curiosity and 
enhancing sexual performance, and their narratives suggested that their sexual performance 
without drugs was within normal limits. Because ED is less common in younger men than older 
men, younger men might conceptualize Viagra and other SEDs as means of enhancing sexual 
experiences as opposed to treating sexual problems. College-age users of SEDs, therefore, might 
not view Viagra as a medical treatment, per se, and thus underestimate the risk of potentially 
adverse outcomes. Although two men alluded to the possibility of experiencing a priapism, most 
of the Viagra users did not express concerns about the possible adverse health effects of taking 
the ED medication, which is concerning considering that many of them reported using other 
substances at the time.  
Comparisons between SED Users and Nonusers 
Participants who endorsed having had used an SED were more likely to have engaged in 
penetrative PAI and did so with more individuals than those who did not endorse having had 
used such substances. Muehlenhard and Shippee (in press) suggested that, for men, PAI might be 
“a proxy for some other characteristic such as being more sexually adventurous, having sex with 
more partners or with partners they did not know well, or having sex in more novel situations” 
(p. 12). This idea is consistent with various findings of the current study. Users repoted having 
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engaged in multiple sexual activities with more partners than those who did not use SEDs, and 
curiosity or experimentation was a commonly endorsed reason for using these substances. The 
act of using a product to enhance sexual performance in itself can be viewed as adventurous, 
particularly considering that most of these men did not report experiencing ED.  
Men who reported SED use endorsed self-enhancement as being a more important reason 
for them to have sex than did the men who did not report SED use. Enhancement motives are 
self-focused and positively reinforcing (Cooper et al., 1998). Considering that they reported 
using substances to enhance sexual performance, their endorsing enhancing pleasure as  more 
important reason for sex than their nonuser counterparts is understandable. Interestingly, this 
motivational difference was not limited to the particular episodes of SED use and extended to 
their sexual behaviors in general.  
We found no group differences in the ages at which users and nonusers engaged in 
various sexual activities for the first time. Although the men who used SEDs did not begin 
experimenting with partnered sexual behaviors before those who did not use them, the former 
group was older than the latter group and thus had more time to engage in these behaviors and to 
do so with more people. The majority of the narratives, however, occurred when the SED users 
were younger than the current mean age of the nonusers (i.e., 9 of the users were younger than 
19.38 when they used the SED).  
Limitations and Future Directions 
 The current study explored male college students’ experiences of using SEDs and 
compared characteristics of these men to those of men who had not used them. Previous research 
suggests a relationship between recreational ED medication use and increased risk for STIs 
(Swearingen & Klausner, 2005). Considering that curiosity and pleasure enhancement emerged 
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as reasons underlying characteristics of the users’ sexual behaviors, it c uld be useful to further 
explore the associations between motivations for sex, SED use, and risky sexual behaviors in 
college men. The current study did not assess risk behaviors such as unprotected sex or outcomes 
such as STIs.  
 Our sample was small and heavily White and heterosexual, limiting generalizability. 
Future research might look at SED use and sex motives in other college-age groups of men. 
Research on more diverse sexual populations would contribute to the literature concerning the 
association between ED medication use and sexual risk behaviors in MSM. It would als  be 
interesting to explore the phenomenon of SED use in college-age women. What substances do 
they use? How do they obtain these substances? Do women who use SEDs endorse enhancement 
motives as more important for having sex than those who do not?  
 We provided broad inclusion criteria for SEDs, which encompassed PDE-5 inhibitors, 
herbal and plant-derived products, topical creams, and Ecstasy in some cases. In contrast to ED 
medications such as Viagra, the herbal products in this study tended to be advertised for sexual 
enhancement rather than treatment. A larger sample might provide insight into differences bas d 
on the substances that men choose to use. For example, do men who use Viagra engage in more 
sexual risk behaviors than those who use nonprescription enhancers? 
Conclusions 
 Male college students reported using substances to enhance sexual performance. Their 
reasons for taking these SEDs focused more on exploration and enhancement and less on actual 
sexual dysfunction. Further research investigating the use of ED medications and other sexual-
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DO NOT PUT YOUR NAME OR KUID ON THIS QUESTIONNAIRE 
This study is about college men’s use of drugs or other substances aimed at enhancing sexual performance. This 
could include the following:  
• Drugs such as Viagra, Cialis, or Levitra.  
• Commercially available performance enhancers such as Enzyte  
• Herbs or other substances, such as maca root, yohimbe extract, goat weed, topical creams, etc. 
 
1. Check which of these applies to you, and follow the dir ctions for that choice. (check one) 
 
 I have used a drug or other substance aimed at enhancing sexual performance (Viagra, Cialis, Levitra, Enzyte, 
herbs, or other substance).  
 DIRECTIONS: Answer the questions on pages 1-5 (questions 2-17) thinking about your experience. If you have 
had more than one experience like this, choose the time that stands out most in your mind. 
 
 I have not used a drug or other substance aimed at enhancing sexual performance, but I have done something 
similar to this.  
 DIRECTIONS: Answer the questions on pages 1-5 (questions 2-17) thinking about your experience. If you have 
had more than one experience like this, choose the time that stands out most in your mind. 
 
 I have not used a drug or other substance aimed at enhancing sexual performance, and I have not done 
something similar to this.  
 DIRECTIONS: Answer the questions on pages 1-5 (questions 2-17) the way you think a guy might if he had 
used these drugs or substances. (The purpose is to protect everyone’s privacy by having everyone write, 
regardless of their experience.) 
 
 
2. Describe a time that you used this drug or substance. I lude:  
• what led up to the situation,  
• what substance you used, and 














Section 1: Continue, describing the same situation as on p. 1. 
 





























Section 1: Continue, describing the same situation as on p. 1. 
 
8. At the time, did you use any alcohol or recreational drugs? If so, what did you use? How, if at all, did this 






9. In which sexual activities did you engage when using the sexual-enhancement drug/substance? 
 No____   Yes____      Kissing 
 No____   Yes____      Having someone stimulate your genitals 
 No____   Yes____      Stimulating someone’s genitals 
 No____   Yes____      Performing oral sex 
 No____   Yes____      Receiving oral sex 
 No____   Yes____      Penile-vaginal intercourse 
 No____   Yes____      Performing penile-anal intercou se  
 No____   Yes____      Receiving penile-anal intercou se  
 No____   Yes____      Masturbation 
 No____   Yes____      Other: ____________________________ 
 
10. If you engaged in sexual activity with someone, what w s your relationship with this person? 
 
 
11. Had you been using a drug or other substance for the purpose of enhancing your mental performance (such as a 













Section 1: Continue, describing the same situation as on p. 1. 
 
12. Had you been using a drug or other substance for the purpose of enhancing your physical performance (such as 
a drug/substance to help you work out or build muscle)? If so, what did you use?  
 
 






13. Had you been using any prescription drugs (such as antidepressants), whether or not they were prescribed to 
you, for medical or mental health purposes? If so, what did you use?  
 
 
How, if at all, did this (in reference to item 13) influence your decision to use the sexual-enhancement 




14. What do you think would have happened if you had not used the sexual-enhancement drug/substance? How do 








Section 1: Continue, describing the same situation as on p. 1. 
 
15. What best describes the relationship(s) you were in at the time you used the sexual-enhancement 
drug/substance? (check one) 
___never dated anyone                         
___not dating anyone at the time                           
___dating one person casually (i.e., with no agreement to be exclusive) 
___dating more than one person casually (i.e., withno agreement to be exclusive) 











17. Have you told anyone that you used the sexual-enhancement drug/substance? If so, who did you tell and why 














Section 2: General Questions 
Regardless of which instructions you followed in Section 1,  
in this section, answer based on your own experiences and opinions.  
 
1. Have you ever used any of the following drugs/substances for the purpose of enhancing sexual performance? If 
so, indicate the number of times you have used it. 
No____   Yes____   Number of times____      Viagra 
No____   Yes____   Number of times____      Cialis 
No____   Yes____   Number of times____      Levitra 
No____   Yes____   Number of times____      Enzyte 
No____   Yes____   Number of times____      Maca Root 
No____   Yes____   Number of times____      Yohimbe Extract 
No____   Yes____   Number of times____      Horny Goat Weed (Epimedium grandiflorum) 
No____   Yes____   Number of times____      Long Jack (Eurycoma longifolia) 
No____   Yes____   Number of times____      Tribulus Terrestris  
No____   Yes____   Number of times____      L-Arginine  
No____   Yes____   Number of times____      Topical cream (specify): _____________________________ 
No____   Yes____   Number of times____      Other (specify): _____________________________ 
 
2. If you have never taken a drug/substance for the purpose of enhancing sexual performance, would you do so if 




3. Have you ever used a drug or other substance for the purpose of enhancing your mental performance (such as a 





4. Have you ever used a drug or other substance for the purpose of enhancing your physical performance (such as 















7. What percentage of time that you have wanted to get r maintain an erection have you had difficulty doing so? 
 
 






















Section 2: General Questions (continued) 
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Section 2: General Questions (continued) 
 





































Section 2: General Questions (continued) 
 
17. How long would you like to be able to maintain an erection before having an orgasm? Explain your answer.  
 
 
18. On average, how long are you able to maintain an erection before having an orgasm? Explain your answer. 
 
 
19. How many sexual encounters would you like to have per month? Explain your answer. 
  
 




21. Think about the last time you engaged in sexual activity with another person. What are some of the reasons why 















Section 2: General Questions (continued) 
 
Listed below are different reasons why people have sex. For each statement, circle the number which best describes 
how important each reason is for you to have sex, from 1 = Not at all important to 5 = Extremely important. 
Remember -- there are no right or wrong answers. We just want to know what you think. Circle your answers. 
 
HOW IMPORTANT IS IT FOR YOU TO HAVE SEX… 





...because it helps you feel better when you’re feeling low? 1 2 3 4 5 
...because people will think less of you if you don’t? 1 2 3 4 5 
…out of fear that your partner won’t love you anymore if you don’t? 1 2 3 4 5 
...to help you feel better about yourself? 1 2 3 4 5 
...to prove to yourself that your partner thinks you’re attractive? 1 2 3 4 5 
...because it helps you feel better when you’re lonly? 1 2 3 4 5 
...to make an emotional connection with your partner? 1 2 3 4 5 
...because you feel “horny?” 1 2 3 4 5 
...to cope with upset feelings? 1 2 3 4 5 
...because it feels good? 1 2 3 4 5 
…just for the excitement of it? 1 2 3 4 5 
...to feel emotionally close to your partner? 1 2 3 4 5 
...because you’re afraid that your partner will leav  you if you don’t? 1 2 3 4 5 
…you worry that your partner won’t want to be with you if you don’t? 1 2 3 4 5 
...to cheer yourself up? 1 2 3 4 5 
...to express love for your partner? 1 2 3 4 5 
...to satisfy your sexual needs? 1 2 3 4 5 
...because it makes you feel more self-confident? 1 2 3 4 5 
...because you don’t want your partner to be angry with you?  1 2 3 4 5 
…just because all your friends are having sex? 1 2 3 4 5 
...because others will kid you if you don’t? 1 2 3 4 5 
...to help you deal with disappointment in your life? 1 2 3 4 5 
...because you worry that people will talk about you if you don’t have sex? 1 2 3 4 5 
...just for the thrill of it? 1 2 3 4 5 
…to show that you are reading this, cross out the one? 1 2 3 4 5 
...because it makes you feel like you’re a more intresting person? 1 2 3 4 5 
…so that others won’t put you down about not having sex? 1 2 3 4 5 
...to become closer with your partner?  1 2 3 4 5 
...to become more intimate with your partner? 1 2 3 4 5 





Section 3: Demographic Questions 
1.    What is your age? _______  
 
2. What is your sexual orientation? (check one) 
_____ Straight (Heterosexual) 
_____ Gay (Homosexual) 
_____ Bisexual 
_____ Unsure 
_____ Other (explain): __________________________ 
 
3. What is your race/ethnicity? 
_____African American / Black 
_____Asian American 
_____European American / White 
_____Hispanic American / Latino  
_____Native American / American Indian 
_____Biracial / Multiracial 
_____Other: _________________________________ 
 
4. Are you an international student?  _____No         _____Yes 
 
5. What best describes your current relationship(s)? (check one) 
___never dated anyone                         
___not dating anyone now                                  
___dating one person casually (i.e., with no agreement to be exclusive) 
___dating more than one person casually (i.e., withno agreement to be exclusive) 















6. Have you done the following in the past year? If so, indicate the number times you have engaged in the activity 
and the number of individuals with whom you have engaged in it during the past year. 
 






# of Times 
 
# of Individuals 
 
Kissing 
    
 
Stimulating someone’s genitals 
    
 
Having someone stimulate your genitals 
    
 
Performing oral sex 
    
 
Receiving oral sex 
    
 
Penile-vaginal sex 
    
 
Performing penile-anal sex 
    
 
Receiving penile-anal sex 
    
 
Other: _________________________ 
















Section 3: Demographic Questions (continued) 
 
7. With how many people have you engaged in sexual activity within the past year? Please include oral sex 
(receiving and/or performing), penile-vaginal sex, and anal sex (receiving and/or performing). 
Number of Individuals: ________ 
8. Have you ever done the following? If so, indicate how old you were the first time you engaged in the activity 
and the number of individuals with whom you have engaged in it. 
 






Age at first time 
 
# of Individuals 
 
Kissing 
    
 
Stimulating someone’s genitals 
    
 
Having someone stimulate your genitals 
    
 
Performing oral sex 
    
 
Receiving oral sex 
    
 
Penile-vaginal sex 
    
 
Performing penile-anal sex 
    
 
Receiving penile-anal sex 
    
 
Other: _________________________ 












Section 3: Demographic Questions (continued) 
 
9. Check the answer that best describes how often you currently masturbate (whatever that means to you), on 
average: (check one)    
 
_____ I have never masturbated. 
_____ I have only masturbated once in my whole life.
_____ I have only masturbated a few times in my whole life. 
_____ I masturbate about once a year. 
_____ I masturbate once every few months. 
_____ I masturbate 1-3 times a month. 
_____ I masturbate once a week. 
_____ I masturbate 2-3 times a week. 
_____ I masturbate 4-6 times a week. 
_____ I masturbate once a day. 
_____ I masturbate more than once a day. 




10. General comments: (Please include any comments that would help us better understand the use of sexual-
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INTRODUCTION:  The Department of Psychology at the University of Kansas supports the practice of protection 
for human subjects participating in research. The following information is provided for you to decide whether you 
wish to participate in the present study. You are fre  to decide whether or not to participate in this study. Even if you 
agree to participate, you are free to withdraw at any time without penalty. If you do withdraw from this study, it will 
not affect the credit you received up to that point. 
 
PURPOSE OF THE STUDY: The purpose of the study is to investigate the use of s xual-enhancement substances 
in male college students. 
 
PROCEDURES and INFORMATION TO BE COLLECTED: This study involves a questionnaire. The 
questionnaire will be anonymous and will take no more than an hour of your time. The questionnaire will ask 
questions about college men’s use of sexual-enhancement substances. Everyone will be able to fill out this
questionnaire, whether or not he has ever had the exp ri nces about which we ask. 
 
ANONYMITY:  The questionnaire is completely anonymous. Nowhere on the questionnaire do we ask for your 
name or KUID, and we have avoided asking questions that might identify you indirectly. As mentioned above, all 
participants will be able to fill out this questionnaire, regardless of their experience.  
 
RISKS and BENEFITS: We do not anticipate that participating in this study will cause any risks. If you are 
uncomfortable with any of the questions, you may skip them. 
 
Regarding benefits, we hope that this study will help us gain a better understanding of the use of sexual-
enhancement substances in college men.  
 
PAYMENTS: Although you will not receive financial compensation f r your time and effort in your participation, 
you will receive one credit toward your research requirement for every half hour or portion thereof that you 
participate. 
 
USE OF THE DATA: The data collected in this study will be used by graduate student Eddie Wright, Professor 
Charlene Muehlenhard, and Professor Muehlenhard’s students to better understand sexual-enhancement substance 
use by college men and its relation to various behaviors and attitudes.  
 
QUESTIONS ABOUT PARTICIPATION: You are free to ask questions during this session. In addition, 
questions about procedures can be directed to the resea chers listed below, and/or to the Human Subjects Committee 
Lawrence Campus (see next section). 
 
PARTICIPANT CERTIFICATION: I have read this Information Sheet. I have had the opportunity to ask, and I 
have received answers to, any questions I had regarding the study. I understand that if I have any additional 
questions about my rights as a research participant, I may call (785) 864-7429 or (785) 864-7385 or write the 
Human Subjects Committee Lawrence Campus (HSCL), University of Kansas, 2385 Irving Hill Road, Lawrence, 
Kansas 66045-7563, email dhann@ku.edu or mdenning@ku.edu.  
 
 






Researcher Contact Information 
 
Eddie Wright, B.A.    Charlene Muehlenhard, Ph.D. 
Principal Investigator    Faculty Supervisor 
Clinical Psychology Graduate Student  Department of Psychology  
ejwright@ku.edu     (785) 864-9860 



























The purpose of this study is to investigate college men’s use of sexual-enhancement substances such as 
Viagra, Cialis, or Levitra, or herbs such as maca root, yohimbe extract, or goat weed. The questionnaire asked 
questions about various aspects of using these substances as well as questions regarding sexual behaviors and 
attitudes. The purpose is to gain a better understanding of the prevalence and qualities of this behavior. 
  
This study is an example of a qualitative study. By a qualitative study, we mean that rather than giving you 
a list of answers to choose from, we asked open-ended questions, and you could answer however you liked.  
 
Many people assume that sexual-enhancement substances such as Viagra are only used by older men 
with erectile difficulties. The results of this study could help us understand the use of these substances 
in college-age men and its relation to their attitudes and behaviors concerning sex. 
 
Thank you for your participation in this study! 
 
 
Because of the nature of this research and the personal questions that it involved answering, you may h ve 
questions or issues that you would like to discuss f rther.  We have provided information about how to contact us in 
case you would like to talk about your feelings concer ing your participation in this study.  We have lso listed the 
phone numbers of some organizations on campus and in Lawrence that provide counseling services in caseyour 
participation in this study has raised some issues that you want to talk about with someone. 
 




The faculty advisor for this study: 
Charlene Muehlenhard, Ph.D. 
Phone:  (785) 864-9860 
Email:  charlene@ku.edu 
 
Counseling services: 
• KU Psychological Clinic, 340 Fraser Hall, (785) 864-4121. Small fee per session. 
• Counseling and Psychological Services (CAPS), Watkins Health Center, (785) 864-9580. Small fee per session. 
• Headquarters Counseling Center, available 24/7, free of charge, for any concern: (785) 841-2345. 
24-hour crisis hotline available, (785) 841-2345.  No charge. 
 
To discuss your rights as a research participant: 
Human Subjects Committee Lawrence, (785) 864-7429  
David Hann, dhann@ku.edu, or Mary Denning, mdenning@ku.edu      





PROTOCOL FOR RUNNING DATA-COLLECTION SESSIONS  
 
 
To Do Prior to the Session: 
 
1. Print a list of the students who have signed up for the study no earlier than 2 hours before the session.  To find 
this, log on to http://ku.sona-systems.com.  Username = xxxx, password = xxxx 
 
Click on My Studies. Click on Muehlenhard - Wright 1 .  Then, scroll down and click on View/Administer Time 
Slots.  You will see the names of students who are signed up for various times.  If no students have signed up two 
hours prior to the start time, the session will automatically be cancelled and you don’t have to show up. To print 
only the names of the people in your timeslot, highlight the names and print the highlighted area.  
 
Research Assistant Timeslots 
 












2.  Pick up our plastic box, which is labeled E die’s Study, in room 452 Fraser. The code for the lockbox is xxxx. 
Put the key back in the lockbox. 
 
3.  Make sure you have enough of the following for y ur sessions: the protocol for data collection, consent forms, 




To Do in the Classroom: 
 
1. Arrive at the room where the testing session will take place 10-15 minutes before the participants are due.   
2. Post sign with study information on the door. 
3. Place consent forms and empty envelopes on altern te chairs or farther apart if there is room. These will be in 
the box.  
4. As students arrive, ask them to print their name legibly on the sign-in sheet. 
5. Tell students as they arrive to sit in seats with consent forms. For the sake of privacy, ask a student to move if 
he or she is too close to another student.  Students should not sit immediately side-by-side. 
6. Two minutes after the session is scheduled to start or once all students who are expected have arrived, shut the 
door and begin introducing the study.  
7. If only one person shows up, be aware that he might feel uncomfortable about it (but don’t assume thathe 
will). Let him know that he can either stay and complete the questionnaire or leave without penalty and sign up 
for a different session where he won't be the only e. (Remind him that he can seal the envelope and that no 
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one will ever know his responses.) If someone decides to leave, let Eddie know. He can cancel their 
participation so they'll be able to sign up again.  Do not bring up the option to leave unless the participant 
expresses discomfort. 
Introducing the Study: 
 
1. Hello!  My name is [YOUR NAME] and this is [THE OTHER RA’S NAME]. We’re members of the 
research team for this study.  We’d like to thank you for being here and for participating in this study.  
 
2. Please be sure that your cell phones are off. 
 
3. On your desk is a consent form which explains what we’ll be asking you to do for this study.  Please 
read it over. (Pause.)   
 
We appreciate your being here and participating in our research.  For this research project we will be 
giving you a questionnaire and asking you to answer some questions.  We promise that all of your 
responses to this questionnaire will remain completely anonymous.  We will give you more information 
about the study when you have completed the questionnaire. 
 
4. Has everyone had a chance to read the consent form? (Pause and wait for people who look like they’re 
reading to finish.)  Are there any questions about it? (Pause)   
 
5. Okay, if you’ve decided to participate in this study, remain in your seat. (People can choose to 
withdraw and still get credits if they want. If anyone wants to leave, ask them to wait briefly while you finish 
introducing the study, or, if convenient, the other RA can talk with them.  Put a mark beside their name on the sign-
up sheet so that you know to give them only one credit.) 
 
6. Pass Out Questionnaires 
We’ll pass out the questionnaires now. (Pass out questionnaires)  
 
7. We’re asking you not to put your name or KUID number anywhere on the questionnaires.  We haven’t 
asked any questions that could identify you.   
 
Does anyone have any questions? 
 
Please take your time filling out the questionnaire; you will have until __:50  to complete it.  When you 
are finished, put it in the envelope and turn it in to us.  You do not have to seal the nvelope, but you may 
do so if you wish.  Do not take out any other materials after you have completed the questionnaire.  Please 
pick up a debriefing form on your way out.   
Please don’t start until I’m finished giving you the instructions. In this questionnaire, you will be 
asked if you have used a drug or other substance aimed at enhancing sexual performance. (Pause) 
The questionnaire has three sections:  
 
Please look at item 1. (Pause and look) If you have used a drug or substance aimed at enhancing 
sexual performance, you will check the first box and answer the questions in Section 1 based on 
your own experiences. (Pause)  
 
If you have not used a drug or substance aimed at enhancing sexual performance but you have 
done something similar, you will check the second box and answer the questions in Section 1 based 




If you have not used a drug or substance aimed at enhancing sexual performance and have not 
done something similar, you will check the third box and answer the questions in Section 1 the way 
you think a guy might if he had used these drugs or substances. Therefore, regardless of whether or 
not you have used these substances, everyone will be responding to the qu stions.  We have done 
this to protect your privacy and to ensure that no one in the session will be able to tell who has or 
has not been in these situations based on who is writing.   
 
Please don’t forget to respond to item 2 on the first page. (Point out item 2) Does anyone have any 
questions? 
 
For the other two sections, starting on page 6, you will answer the questions based on your own 
experiences, regardless of the instructions you followed in Section 1. 
 
Please be sure to read the instructions and complete all parts of the questionnaire. 
 
Again, make sure that your cell phones are turned off. 
 
Does anyone have any questions? (pause) If you have questions once you start, come up to the front, 
and we’ll try to answer them. OK, you can begin. 
 
To Do While Students Are Completing Questionnaires: 
 
1. If a participant arrives a little late  (5-10 minutes late) and you think that they might have time to finish, one 
RA can give them the consent form and explain the questionnaire quietly in a corner of the room or in the
hallway.  
 
 If a participant arrives very little late  (more than 10 minutes late), let them know they can sign up for a new 
time within one week without penalty. If there is another session scheduled immediately after, offer th m the 
opportunity to begin late and finish up during the next session.   
 
2. Try to keep busy (e.g., read a book or do homework) during the session so that participants do not feel self-
conscious. Do not stare at them or glance at their answers. Keep discussion with the other RA to a minimum, 
and if you need to talk to each other, do so quietly. 
 
3. When students have finished with the study, write their finish time on the sign-in sheet.  Hand participants 
debriefing forms on their way out.  Be sure to write the date, number of credits to be awarded, and your 
initials on the debriefing form. Each student who completes the study will get two credits.  
 
4. If there is no clock in the room, at __: 40 tellhe participants that there are 10 minutes left to complete the 
questionnaire.  At __: 45 tell the participants that t ere are 5 minutes left to complete the questionnaire.  With 5 
minutes left, tell any remaining students to finish up. 
 
5. At __: 50 when the time is up, ask any remaining participants to place their questionnaires in the envelopes and 
turn them in to you. 
 
 
To Do After All Students Have Left: 
 
1. Put everything away, and pick up any extra forms in the room.  Take down the sign on the door. 
 
2. Leave the sign-in sheets in the box. 
 
3. Keep the questionnaires with you in a safe and secure place until you turn them in to Room 452 Fraser 
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(in the cardboard box labeled Eddie’s Completed Questionnaires). 
 
 Do not take the questionnaires out of the envelopes.  Remember that we have promised our participants 
anonymity, so do not look at the questionnaires that have just been turned in. 
 
4. The RA who takes the box back to the research space (FR 452) is responsible for making sure it is socked with 
paperwork and envelopes.  If there are 15 or fewer copies of materials, let Eddie know what is needed an  he 
will make copies. 
 
5.    If anything unusual happened during the session that might affect the validity of the responses, email Charlene 
(charlene@ku.edu) and Eddie (ejwright@ku.edu).  
 
6. If a participant does not show up for a scheduled time, send his name to Eddie.  The participant will be 
offered the opportunity to sign up for a new time within one week without penalty. 
 
7.    Assign Credit:  Log on to http://ku.sona-systems.com with the username =xxxx and password =xxxx. Click on 
My Studies. Click on Muehlenhard - Wright 1. Click on view/administer timeslots and assign credit.  
Participants who completed the study receive 2 credits; those who showed up but chose to withdraw before 
completing the study get 1 credit for every 30 minutes (or portion thereof) that they participated.  Credit must 
be assigned within 48 hours of completion of the study. 
 
 
 
 
 
